Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression.

CONCLUSIONS: Our findings suggest that early identification of this aggressive form of prostate cancer offers potential for improved outcomes with early introduction of PARP inhibitor-based therapy.
PMID: 31796516 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 2, 2019 Category: Cancer & Oncology Authors: Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, Mucci LA, Lee GM, Nanjangud GJ, Kantoff PW Tags: Clin Cancer Res Source Type: research